NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that the underwriters of its recently announced $2.2 billion public offering of common stock have exercised their over-allotment option.

The underwriters purchased nearly 3.9 million additional shares of Thermo Fisher's stock at $85.50 per share in exercising the over-allotment option.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.